First Trust SMID Growth Strength ETF
Limited financial coverage for FSGS.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The First Trust SMID Growth Strength ETF (the "Fund") aims to deliver investment performance that broadly matches the price movements and income generation (before accounting for the Fund's own fees and expenses) of an equity benchmark, specifically The SMID Growth Strength Index (the "Index"). Ordinarily, the Fund will allocate a minimum of 80% of its net assets (which may include funds borrowed for investment purposes) to the securities that constitute this Index.
- IPO
- 2017
- HQ
- Wheaton, IL, US
Get TickerSpark's AI analysis on FSGS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.94M
- Div Yield
- 0.03%
- 52W High
- $34.16
- 52W Low
- $28.35
- 50D MA
- $33.05
- 200D MA
- $31.41
- Beta
- 0.99
- RSI (14)
- 52
- Avg Volume
- 1.07K
No earnings-call transcripts are available for FSGS yet.
- Free Float
- 0.0%
- Shares Outstanding
- 949.93K
- Float Shares
- 0
Our FSGS coverage
Recent articles, reports, and earnings notes.
No research on FSGS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FSGS report →CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
gurufocus.com · Oct 4
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G
gurufocus.com · Sep 23
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
gurufocus.com · Jul 8
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
gurufocus.com · Jun 4
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
gurufocus.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.